Cayuga Biotech, Inc.

NEW YORK--( BUSINESS WIRE )--Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to heal and stop bleeding, today presented preclinical data on its first generation, first-in-class, polyphosphate (polyP)-based therapy designed to address life-threatening hemorrhage. The results demonstrated that the infused polyP-SNP (silica nanoparticle) complex was able to overcome conditions known to be associated with poor survival after injury with hemorrhage, known as the “lethal triad”—hemodilution, acidemia, and hypothermia. These data were presented as a poster presentation at the Military Health System Research Symposium in Kissimmee, FL. “Bleeding is the leading cause of preventable death after traumatic injury in the battlefield, in large part due to the difficulty in treating non-compressible hemorrhage, such as from penetrating injury,” said Charles Pollack, MD, emergency medicine physician at the University of Mississippi and previously, Regimental Surgeon, 4 th Marines, US Navy Medical Corps. “These data are exciting because this novel polyP-SNP complex can overcome some of the most challenging clinical conditions to help restore the ability to clot.” Data presented in the “Technologies for the Treatment of Battlefield Hemorrhage and Management of Vascular Dysfunction” session demonstrated normalized thrombin generation and clotting under extreme hemodilute conditions in which normal plasma failed. Improved coagulation was also observed under severe acidotic and hypothermic conditions. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response without driving excess clotting, a problem that has limited development for other injectable drugs to treat hemorrhage. Poster Session 1: “A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions” About Hemorrhage Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death. About Cayuga Biotech, Inc. Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com .

Novel therapy also shows low potential for off-target effects NEW YORK--(BUSINESS WIRE)-- Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to heal and stop bleeding, today presented preclinical data on its first generation, first-in-class, polyphosphate (polyP)-based therapy designed to address life-threatening hemorrhage. The results demonstrated that the polyP-SNP (silica nanoparticle) complex, in both standard and lethal triad conditions in vitro and ex vivo, generated thrombin 12 times faster than control, resulting in faster clotting with low potential for off-target thromboembolism. These data were presented in both oral and poster presentations at the Annual Meeting of the International Society for Thrombosis and Haemostasis in Bangkok, Thailand. “The potential of exogenous polyP to stop noncompressible hemorrhage has previously been limited by its inability to be delivered systemically,” said study co-author James Morrissey, PhD, Professor of Biological Chemistry and Internal Medicine, Cardiology at the University of Michigan, who also led the characterization of polyphosphate’s hemostatic properties in humans. “These data are exciting because this novel polyP-SNP complex has overcome these limitations while demonstrating superior clotting in both standard and simulated ‘lethal triad’ (hemodilution, hypothermia and acidosis) conditions that compromise the body’s ability to stop bleeding.” Data presented in the ISTH “New strategies for reversal and prevention of bleeding” session demonstrated faster clotting in vitro and ex vivo and acceleration of thrombin generation, which is the critical factor that determines the ability to clot quickly and effectively. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response without driving excess clotting. The activity of polyP-SNP complex is independent of FXII activation, which suggests a low potential for causing clotting in healthy tissue, a problem that has limited development for other injectable drugs to treat hemorrhage. The study abstracts are available on the ISTH website at . “A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), has pro-hemostatic activities as assessed by in vitro and ex vivo studies” (OC 43.2) “A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions” (PB1047) About Hemorrhage Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death. About Cayuga Biotech, Inc. Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit . View source version on businesswire.com: Contacts Andrea Ashford-Hicks Media@cayugabiotech.com Source: Cayuga Biotech, Inc. View this news release online at: